Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Recent advances in the management of mucormycosis: from bench to bedside.

Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS.

Clin Infect Dis. 2009 Jun 15;48(12):1743-51. doi: 10.1086/599105. Review.

2.

Combination therapy for mucormycosis: why, what, and how?

Spellberg B, Ibrahim A, Roilides E, Lewis RE, Lortholary O, Petrikkos G, Kontoyiannis DP, Walsh TJ.

Clin Infect Dis. 2012 Feb;54 Suppl 1:S73-8. doi: 10.1093/cid/cir885.

3.

Recent advances in the treatment of mucormycosis.

Spellberg B, Ibrahim AS.

Curr Infect Dis Rep. 2010 Nov;12(6):423-9. doi: 10.1007/s11908-010-0129-9.

4.

Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.

Ibrahim AS, Gebremariam T, Luo G, Fu Y, French SW, Edwards JE Jr, Spellberg B.

Antimicrob Agents Chemother. 2011 Apr;55(4):1768-70. doi: 10.1128/AAC.01577-10. Epub 2011 Jan 24.

5.

Combination echinocandin-polyene treatment of murine mucormycosis.

Ibrahim AS, Gebremariam T, Fu Y, Edwards JE Jr, Spellberg B.

Antimicrob Agents Chemother. 2008 Apr;52(4):1556-8. doi: 10.1128/AAC.01458-07. Epub 2008 Jan 22.

6.

Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis.

Reed C, Bryant R, Ibrahim AS, Edwards J Jr, Filler SG, Goldberg R, Spellberg B.

Clin Infect Dis. 2008 Aug 1;47(3):364-71. doi: 10.1086/589857.

7.

Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.

Riley TT, Muzny CA, Swiatlo E, Legendre DP.

Ann Pharmacother. 2016 Sep;50(9):747-57. doi: 10.1177/1060028016655425. Epub 2016 Jun 15. Review.

PMID:
27307416
8.

The iron chelator deferasirox protects mice from mucormycosis through iron starvation.

Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, Schwartz J, Skory CD, Edwards JE Jr, Spellberg BJ.

J Clin Invest. 2007 Sep;117(9):2649-57.

9.

Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia.

Rickerts V, Atta J, Herrmann S, Jacobi V, Lambrecht E, Bialek R, Just-Nübling G.

Mycoses. 2006;49 Suppl 1:27-30.

PMID:
16961579
10.

Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.

Reed C, Ibrahim A, Edwards JE Jr, Walot I, Spellberg B.

Antimicrob Agents Chemother. 2006 Nov;50(11):3968-9. Epub 2006 Sep 25. No abstract available.

11.

Mucormycosis: New Developments into a Persistently Devastating Infection.

Danion F, Aguilar C, Catherinot E, Alanio A, DeWolf S, Lortholary O, Lanternier F.

Semin Respir Crit Care Med. 2015 Oct;36(5):692-705. doi: 10.1055/s-0035-1562896. Epub 2015 Sep 23. Review.

PMID:
26398536
12.

Successful treatment of rhino-orbital mucormycosis with posaconazole and hyperbaric oxygen therapy.

Almannai M, Imran H, Estrada B, Siddiqui AH.

Pediatr Hematol Oncol. 2013 Apr;30(3):184-6. doi: 10.3109/08880018.2013.770587. Epub 2013 Feb 27.

PMID:
23444832
13.

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.

Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, Fredricks D, Brass EP.

J Antimicrob Chemother. 2012 Mar;67(3):715-22. doi: 10.1093/jac/dkr375. Epub 2011 Sep 20.

14.

Current and future therapeutic options in the management of invasive aspergillosis.

Krishnan-Natesan S, Chandrasekar PH.

Drugs. 2008;68(3):265-82. Review.

PMID:
18257606
15.

Deferasirox as adjunctive therapy for mucormycosis.

Donnelly JP, Lahav M.

J Antimicrob Chemother. 2012 Mar;67(3):519-20. doi: 10.1093/jac/dkr540. Epub 2011 Dec 20.

PMID:
22186877
16.

Cerebral mucormycosis in a diabetic man.

Uy EM, Rustagi T, Khera S.

Conn Med. 2011 May;75(5):273-9.

PMID:
21678839
17.

Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies.

Abidi MZ, Sohail MR, Cummins N, Wilhelm M, Wengenack N, Brumble L, Shah H, Jane Hata D, McCullough A, Wendel A, Vikram HR, Kusne S, Litzow M, Letendre L, Lahr BD, Poeschla E, Walker RC.

Mycoses. 2014 Nov;57(11):687-98. doi: 10.1111/myc.12222. Epub 2014 Jul 18.

18.

Clinical experience with posaconazole in patients with invasive mucormycosis: a case series.

González-Ramos MM, Bertrán-Pasarell J, Guiot H, Soto R, Santana J, Amador R, Conde A.

P R Health Sci J. 2008 Dec;27(4):328-32.

PMID:
19069358
19.

Successful nonoperative management of gastrointestinal mucormycosis: novel therapy for invasive disease.

Mezhir JJ, Mullane KM, Zarling J, Satoskar R, Pai RK, Roggin KK.

Surg Infect (Larchmt). 2009 Oct;10(5):447-51. doi: 10.1089/sur.2008.049. Review.

PMID:
19485785
20.

Mucormycosis may mimic disease relapse in Wegener's granulomatosis.

Nogueira EL, Ind PW, Friedland JS, Salama AD.

J Rheumatol. 2010 Jun;37(6):1364-5. doi: 10.3899/jrheum.091423. No abstract available.

PMID:
20516047

Supplemental Content

Support Center